Immediate Management of Mania in a 21-Year-Old Woman on Dextroamphetamine
Stop dextroamphetamine immediately and initiate an atypical antipsychotic (aripiprazole 10–15 mg daily or risperidone 2 mg daily) combined with a mood stabilizer (lithium or valproate) for acute mania. 1, 2
Step 1: Discontinue the Stimulant
Dextroamphetamine is directly causing or exacerbating the manic episode and must be stopped immediately. 3, 4
- Amphetamines induce mania in susceptible individuals, with a dose-response relationship showing that doses >30 mg dextroamphetamine equivalents (this patient is on 60 mg/day total) are associated with 5.28-fold increased odds of psychosis or mania. 5
- The FDA label explicitly warns that "CNS stimulants may induce a manic or mixed episode in patients" and advises screening for risk factors including "comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression" before initiating treatment. 3
- Drug-induced mania from sympathomimetic amines like dextroamphetamine is well-documented, with discontinuation of the inciting drug being the most efficacious first-line intervention. 4, 6
- Do not taper the stimulant—abrupt discontinuation is appropriate in acute mania, as the risk of continuing the causative agent far outweighs any withdrawal concerns. 6
Step 2: Initiate Combination Antimanic Therapy
Start an atypical antipsychotic plus a mood stabilizer immediately for rapid symptom control and long-term stabilization. 1, 2
First-Line Antipsychotic Options:
- Aripiprazole 10–15 mg daily provides rapid control of manic symptoms with a favorable metabolic profile, making it ideal for a young woman. 1, 2
- Risperidone 2 mg/day is equally effective when combined with mood stabilizers and offers rapid symptom control. 2
- Olanzapine 10–15 mg/day provides the most rapid antimanic effect but carries higher metabolic risk (weight gain, diabetes); reserve for severe presentations unresponsive to aripiprazole or risperidone. 2
First-Line Mood Stabilizer Options:
Lithium (target 0.8–1.2 mEq/L for acute treatment) is the gold standard, with unique anti-suicidal properties (reduces suicide attempts 8.6-fold and completed suicides 9-fold). 1
Valproate (target 50–100 µg/mL) may be preferred if rapid loading is needed or if the patient has mixed features/irritability. 1
Combination therapy (antipsychotic + mood stabilizer) is superior to monotherapy for severe mania and represents first-line treatment. 1, 2
Step 3: Adjunctive Benzodiazepine for Acute Agitation
If severe agitation is present, add lorazepam 1–2 mg every 4–6 hours as needed for the first few days. 2
- The combination of an antipsychotic with a benzodiazepine provides superior acute agitation control compared to either agent alone. 2
- Time-limit benzodiazepine use to days-to-weeks to avoid tolerance and dependence. 2
Step 4: Baseline Assessment and Monitoring
Before Starting Medications:
- Metabolic baseline (for antipsychotic): BMI, waist circumference, blood pressure, fasting glucose, fasting lipid panel. 1, 2
- Mood stabilizer baseline: See lithium or valproate requirements above. 1
- Pregnancy test is mandatory in a woman of childbearing age before starting any mood stabilizer. 1
Ongoing Monitoring:
- Weekly psychiatric assessment during the first month using standardized measures (e.g., Young Mania Rating Scale if available). 2
- Lithium levels every 3–6 months once stable, along with renal and thyroid function. 1
- Valproate levels every 3–6 months, along with liver function and CBC. 1
- Metabolic monitoring for antipsychotics: BMI monthly for 3 months then quarterly; blood pressure, fasting glucose, and lipids at 3 months then yearly. 1, 2
Step 5: Maintenance and Long-Term Planning
Continue combination therapy for at least 12–24 months after achieving mood stabilization. 1, 2
- Premature discontinuation leads to relapse rates exceeding 90% in noncompliant patients versus 37.5% in compliant patients. 1, 2
- Withdrawal of maintenance lithium therapy dramatically increases relapse risk within 6 months, especially if discontinued abruptly. 1
- Some patients will require lifelong treatment when benefits outweigh risks. 1, 2
Step 6: Addressing the Underlying ADHD (After Mood Stabilization)
Do not restart stimulants until mood symptoms are fully stabilized for at least 12 weeks on a mood stabilizer regimen. 1
- For patients with comorbid ADHD and bipolar disorder, stimulant medications may be reintroduced only after mood stabilization is achieved. 1
- A randomized controlled trial showed that low-dose mixed amphetamine salts were safe and effective for comorbid ADHD only after mood symptoms were stabilized with divalproex. 7
- Alternative ADHD treatments to consider instead of stimulants:
Common Pitfalls to Avoid
- Never use antidepressants or stimulants as monotherapy in bipolar disorder, as this can trigger manic episodes or rapid cycling. 1, 2
- Do not underdose the antipsychotic—aripiprazole requires 10–15 mg/day for acute mania, and inadequate dosing delays therapeutic response. 2
- Do not assume the mania will resolve with stimulant discontinuation alone—active antimanic treatment is required. 4, 6
- Systematic medication trials require 6–8 weeks at adequate doses before concluding an agent is ineffective. 2
- Never restart stimulants before mood stabilization is achieved, as this will precipitate relapse. 1
Psychosocial Interventions
Combine pharmacotherapy with psychoeducation and psychosocial interventions to improve outcomes. 1, 2
- Provide comprehensive psychoeducation covering symptoms, course of illness, treatment options, and the critical importance of medication adherence. 1, 2
- Cognitive-behavioral therapy has strong evidence for both anxiety and depression components of bipolar disorder once acute symptoms stabilize. 1, 2
- Family-focused therapy helps with medication supervision, early warning sign identification, and reducing access to lethal means. 1, 2